66 results on '"Braibant M"'
Search Results
2. Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups of HIV-1
- Author
-
Braibant M, Gong E, Plantier J, Simon F, and Barin F
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2012
- Full Text
- View/download PDF
3. The breadth of maternal HIV-1 specific neutralizing antibodies is not associated with a lower risk of mother-to-infant transmission
- Author
-
Chaillon A, Wack T, Braibant M, Mandelbrot L, Blanche S, Warszawski J, and Barin F
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2012
- Full Text
- View/download PDF
4. P04-17. The N-glycosylation sites N295, N332 and N392 of gp120 are necessary but not sufficient for HIV-1 to be neutralized by 2G12
- Author
-
Barin F, Autran B, Braibant M, and Chaillon A
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2009
- Full Text
- View/download PDF
5. Antimycobacterial activity of synthetic pamamycins
- Author
-
Lefèvre, P., Peirs, P., Braibant, M., Fauville-Dufaux, M., Vanhoof, R., Huygen, K., Wang, X.-M., Pogell, B., Wang, Y., Fischer, P., Metz, P., and Content, J.
- Published
- 2004
6. Effect of amino acid substitutions within the V3 region of HIV-1 CRF01_AE on interaction with CCR5-coreceptor
- Author
-
Hongjaisee, S., Braibant, M., Barin, F., Ngo-Giang-Huong, Nicole, Sirirungsi, W., and Samleerat, T.
- Subjects
coreceptor usage ,V3 ,viruses ,HIV-1 ,virus diseases ,CRF01_AE ,CCR5 - Abstract
Specific amino acids within the V3 loop of HIV-1 CRF01_AE envelope glycoprotein that are involved in the interaction with CCR5/CXCR4 coreceptors, are not well characterized. We generated V3 mutants using polymerase chain reaction (PCR)-based site-directed mutagenesis of HIV-1 CRF01_AE R5-env plasmids at specific positions. Mutant viruses were produced by env-pseudotyped virus assay, tested for coreceptor usage using U373.R5 and U373.X4 cells, and viral entry was assessed with luciferase activity measurement. All viruses, harboring either single or double mutations, used the CCR5 coreceptor. However, those containing a single substitution at positions 7, 11, 18, and 32 and those with mutations at positions 5/32 and 18/32 had reduced infectivity. Only virus with arginine substitution at position 11 seemed to be involved in CXCR4 coreceptor usage. Our results suggest that some V3 positions may be necessary for the binding to coreceptor, but not for the switch of coreceptor usage.
- Published
- 2017
7. Structural and functional study of Salmonella enterica serovar Typhimurium DT104 floR, an efflux pump belonging to the major facilitator superfamily
- Author
-
Braibant, M., Chaslus-Dancla, E., Cloeckaert, Axel, Station de Pathologie aviaire et parasitologie [Nouzilly] (PAP), Institut National de la Recherche Agronomique (INRA), and ProdInra, Migration
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
National audience
- Published
- 2003
8. Stability of Concentrated Solution of Vancomycin Hydrochloride in Syringes for Intensive Care Units
- Author
-
Godet Marie, Simar Joanna, Closset Mélanie, Hecq Jean-Daniel, Braibant Maximilien, Soumoy Laura, Gillet Patricia, Jamart Jacques, Bihin Benoît, and Galanti Laurence
- Subjects
vancomycin infusions ,concentrated solutions ,high performance liquid chromatography ,physicochemical stability ,syringe ,intensive care units ,Therapeutics. Pharmacology ,RM1-950 ,Pharmaceutical industry ,HD9665-9675 - Abstract
Vancomycin is increasingly administrated by continuous infusion. But the treatment of patient in intensive care need restricted volume to prevent fluid overload. The aim of the study was to evaluate the physical and chemical stability of solutions of a high concentration of vancomycin hydrochloride in 5 % glucose or 0.9 % NaCl.
- Published
- 2018
- Full Text
- View/download PDF
9. Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01 AE.
- Author
-
Samleerat T, Braibant M, Jourdain G, Moreau A, Ngo-Giang-Huong N, Leechanachai P, Hemvuttiphan J, Hinjiranandana T, Changchit T, Warachit B, Suraseranivong V, Lallemant M, and Barin F
- Abstract
We analyzed the characteristics of the envelope genes of human immunodeficiency virus type 1 in 17 mother-infant pairs infected with variants of the CRF01_AE clade. A total of 353 sequences covering almost the entire glycoprotein (gp) 120 region were available for analysis. We found that, even if the virus population in the mother was complex, only viruses of a restricted subset were transmitted to her infant, independently of whether transmission occurred in utero or during the intrapartum period. We did not find that shorter gp120 regions or fewer potential N-glycosylation sites (PNGS) were characteristic of viruses transmitted from mother to infant. However, our data suggest that a limited number of PNGS that seem to be conserved in all variants in infants but are not uniformly present in variants in mothers may confer an advantage for transmission of the virus, thereby highlighting the potentially important role of the 'glycan shield.' This finding was particularly significant for the PNGS at positions N301 and N384. Copyright © 2008 Infectious Diseases Society of America [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
10. Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission in Thailand
- Author
-
Moreau Alain, Ngo-Giang-Huong Nicole, Jourdain Gonzague, Samleerat Tanawan, Thenin Suzie, Leechanachai Pranee, Lallemand Marc, Barin Françis, and Braibant Martine
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2009
- Full Text
- View/download PDF
11. Characteristics of HIV-1 gp120 env sequences in mother-child pairs infected with HIV-1 subtype CRF01_AE
- Author
-
Hemvuttiphan Jittapol, Hinjiranandana Temsiri, Leechanachai Pranee, Ngo-Giang-Huong Nicole, Moreau Alain, Jourdain Gonzague, Braibant Martine, Samleerat Tanawan, Changchit Tikamporn, Warachit Boonyarat, Suraseranivong Veera, Lallemant Marc, and Barin Francis
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2008
- Full Text
- View/download PDF
12. Drift of the HIV-1 Envelope Glycoprotein gp120 toward Increased Neutralization Resistance over the Course of the Epidemic: a Comprehensive Study Using the Most Potent and Broadly Neutralizing Monoclonal Antibodies.
- Author
-
Bouvin-Pley, M., Morgand, M., Meyer, L., Goujard, C., Moreau, A., Mouquet, H., Nussenzweig, M., Pace, C., Ho, D., Bjorkman, P. J., Baty, D., Chames, P., Pancera, M., Kwong, P. D., Poignard, P., Barin, F., and Braibant, M.
- Subjects
- *
HIV , *GLYCOPROTEINS , *MONOCLONAL antibodies , *EPITOPES , *CELL membranes - Abstract
Extending our previous analyses to the most recently described monoclonal broadly neutralizing antibodies (bNAbs), we confirmed a drift of HIV-1 clade B variants over 2 decades toward higher resistance to bNAbs targeting almost all the identified gp120-neutralizing epitopes. In contrast, the sensitivity to bNAbs targeting the gp41 membrane-proximal external region remained stable, suggesting a selective pressure on gp120 preferentially. Despite this evolution, selected combinations of bNAbs remain capable of neutralizing efficiently most of the circulating variants. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Role of Viral Envelope Proteins in Determining Susceptibility of Viruses to IFITM Proteins.
- Author
-
Marceau T and Braibant M
- Subjects
- Interferons pharmacology, Membrane Proteins genetics, Membrane Proteins metabolism, Cell Membrane metabolism, Virus Internalization, Viral Envelope Proteins, HIV-1 physiology
- Abstract
Interferon-induced transmembrane proteins (IFITMs) are a family of proteins which inhibit infections of various enveloped viruses. While their general mechanism of inhibition seems to be non-specific, involving the tightening of membrane structures to prevent fusion between the viral envelope and cell membrane, numerous studies have underscored the importance of viral envelope proteins in determining the susceptibility of viruses to IFITMs. Mutations in envelope proteins may lead to viral escape from direct interaction with IFITM proteins or result in indirect resistance by modifying the viral entry pathway, allowing the virus to modulate its exposure to IFITMs. In a broader context, the nature of viral envelope proteins and their interaction with IFITMs can play a crucial role in the context of adaptive immunity, leading to viral envelope proteins that are more susceptible to antibody neutralization. The precise mechanisms underlying these observations remain unclear, and further studies in this field could contribute to a better understanding of how IFITMs control viral infections.
- Published
- 2024
- Full Text
- View/download PDF
14. Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller.
- Author
-
Molinos-Albert LM, Baquero E, Bouvin-Pley M, Lorin V, Charre C, Planchais C, Dimitrov JD, Monceaux V, Vos M, Hocqueloux L, Berger JL, Seaman MS, Braibant M, Avettand-Fenoël V, Sáez-Cirión A, and Mouquet H
- Subjects
- Humans, Broadly Neutralizing Antibodies, HIV Antibodies, Antibodies, Neutralizing, Viremia, Antigens, Viral, Polysaccharides, env Gene Products, Human Immunodeficiency Virus, HIV-1, HIV Infections drug therapy
- Abstract
HIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usually unable to counteract autologous viruses escaping the antibody pressure. Nonetheless, bNAbs may contribute to natural HIV-1 control in individuals off antiretroviral therapy (ART). Here, we describe a bNAb B cell lineage elicited in a post-treatment controller (PTC) that exhibits broad seroneutralization and show that a representative antibody from this lineage, EPTC112, targets a quaternary epitope in the glycan-V3 loop supersite of the HIV-1 envelope glycoprotein. The cryo-EM structure of EPTC112 complexed with soluble BG505 SOSIP.664 envelope trimers revealed interactions with N301- and N156-branched N-glycans and the
324 GDIR327 V3 loop motif. Although the sole contemporaneous virus circulating in this PTC was resistant to EPTC112, it was potently neutralized by autologous plasma IgG antibodies. Our findings illuminate how cross-neutralizing antibodies can alter the HIV-1 infection course in PTCs and may control viremia off-ART, supporting their role in functional HIV-1 cure strategies., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
15. Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller.
- Author
-
Lorin V, Fernández I, Masse-Ranson G, Bouvin-Pley M, Molinos-Albert LM, Planchais C, Hieu T, Péhau-Arnaudet G, Hrebík D, Girelli-Zubani G, Fiquet O, Guivel-Benhassine F, Sanders RW, Walker BD, Schwartz O, Scheid JF, Dimitrov JD, Plevka P, Braibant M, Seaman MS, Bontems F, Di Santo JP, Rey FA, and Mouquet H
- Subjects
- Animals, Antibodies, Neutralizing, Broadly Neutralizing Antibodies, Elite Controllers, Epitopes, HIV Antibodies, Humans, Immunoglobulin A, Immunoglobulin G, Mice, Polysaccharides, env Gene Products, Human Immunodeficiency Virus, HIV Infections, HIV-1
- Abstract
Decrypting the B cell ontogeny of HIV-1 broadly neutralizing antibodies (bNAbs) is paramount for vaccine design. Here, we characterized IgA and IgG bNAbs of three distinct B cell lineages in a viremic controller, two of which comprised only IgG+ or IgA+ blood memory B cells; the third combined both IgG and IgA clonal variants. 7-269 bNAb in the IgA-only lineage displayed the highest neutralizing capacity despite limited somatic mutation, and delayed viral rebound in humanized mice. bNAbs in all three lineages targeted the N332 glycan supersite. The 2.8-Å resolution cryo-EM structure of 7-269-BG505 SOSIP.664 complex showed a similar pose as 2G12, on an epitope mainly composed of sugar residues comprising the N332 and N295 glycans. Binding and cryo-EM structural analyses showed that antibodies from the two other lineages interact mostly with glycans N332 and N386. Hence, multiple B cell lineages of IgG and IgA bNAbs focused on a unique HIV-1 site of vulnerability can codevelop in HIV-1 viremic controllers., Competing Interests: Disclosures: F.A. Rey is a board member of EureKARE and MELETIUS Therapeutics. No other disclosures were reported., (© 2022 Lorin et al.)
- Published
- 2022
- Full Text
- View/download PDF
16. Escape of HIV-1 envelope glycoprotein from the restriction of infection by IFITM3.
- Author
-
Drouin A, Migraine J, Durand MA, Moreau A, Burlaud-Gaillard J, Beretta M, Roingeard P, Bouvin-Pley M, and Braibant M
- Abstract
Interferon-induced transmembrane protein 3 (IFITM3) is a cellular factor that reduces HIV-1 infectivity by an incompletely understood mechanism. We show here that viruses differing only in the envelope glycoprotein (Env) expressed on their surface have different sensitivities to IFITM3. Measurements of the sensitivity of viruses to neutralizing antibodies showed that IFITM3 increased the sensitivity of IFITM3-sensitive viruses to PG16, which targets the V1V2 loop, suggesting that IFITM3 promotes exposure of the PG16 epitope of IFITM3-sensitive viruses. Exchanges of V1V2 loops between the Env proteins of sensitive and resistant viruses revealed that V1V2 and V3 act together to modulate viral sensitivity to IFITM3. Co-immunoprecipitation experiments showed that IFITM3 interacted with both the precursor (gp160) and cleaved (gp120) forms of Env from IFITM3-sensitive viruses, but only with the precursor (gp160) form of Env from IFITM3-resistant viruses. This finding suggests that the interaction between the Env of resistant viruses and IFITM3 was inhibited once Env had been processed in the Golgi apparatus. This hypothesis was supported by immunofluorescence experiments, which showed a strong colocalization of IFITM3 with the Env of sensitive viruses, but only weak colocalization with the Env of resistant viruses on the plasma membrane of virus-producing cells. Together, these results indicate that IFITM3 interacts with Env, inducing conformational changes that may decrease viral infectivity. This antiviral action is, nevertheless, modulated by the nature of the Env, in particular its V1V2 and V3 loops, which after maturation may be able to escape this interaction. IMPORTANCE Interferon-induced transmembrane protein 3 (IFITM3) is a cellular factor that reduces HIV-1 infectivity by an incompletely understood mechanism. This study aimed to elucidate the role of the HIV-1 envelope glycoprotein (Env) in determining viral susceptibility to IFITM3. We found that viruses differing only in Env expressed on their surface had different sensitivities to IFITM3. By comparing the Env proteins of viruses that were highly sensitive or resistant to IFITM3, we obtained new insight in the mechanisms by which HIV-1 escapes this protein. We showed that IFITM3 interacts with the Env protein of sensitive viruses in virion-producing cells, inducing conformational changes that may decrease viral infectivity. However, this antiviral action is modulated by the nature of Env, particularly the V1V2 and V3 loops, which may be able to escape this interaction after processing in the Golgi., (Copyright © 2020 American Society for Microbiology.)
- Published
- 2021
- Full Text
- View/download PDF
17. A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors.
- Author
-
Diallo MS, Samri A, Charpentier C, Bertine M, Cheynier R, Thiébaut R, Matheron S, Collin F, Braibant M, Candotti D, Brun-Vézinet F, and Autran B
- Subjects
- Antiviral Restriction Factors, CD4-Positive T-Lymphocytes, HIV Long-Term Survivors, HIV-2, Humans, Tripartite Motif Proteins, Ubiquitin-Protein Ligases, HIV Infections, HIV-1
- Abstract
Human immunodeficiency viruses induce rare attenuated diseases due either to HIV-1 in the exceptional long-term nonprogressors (LTNPs) or to HIV-2 in West Africa. To better understand characteristics of these two disease types we performed a multiplex comparative analysis of cell activation, exhaustion, and expression of coreceptors and restriction factors in CD4 T cells susceptible to harbor those viruses. We analyzed by flow cytometry the expression of HLA-DR, PD1, CCR5, CXCR6, SAMHD1, Blimp-1, and TRIM5α on CD4 T cell subsets from 10 HIV-1
+ LTNPs and 14 HIV-2+ (12 nonprogressors and 2 progressors) of the ANRS CO-15 and CO-5 cohorts, respectively, and 12 HIV- healthy donors (HD). The V3 loop of the HIV-1 envelope from 6 HIV-1+ LTNPs was sequenced to determine the CXCR6-binding capacity. Proportions of HLA-DR+ and PD1+ cells were higher in memory CD4 T subsets from HIV-1 LTNPs compared with HIV-2 and HD. Similar findings were observed for CCR5+ cells although limited to central-memory CD4 T cell (TCM) and follicular helper T cell subsets, whereas all major subsets from HIV-1 LTNPs contained less CXCR6+ cells compared with HIV-2. All six V3 loop sequences from HIV-1 LTNPs contained a proline at position 326. Proportions of SAMHD1+ cells were higher in all resting CD4 T subsets from HIV-1 LTNPs compared with the other groups, whereas Blimp-1+ and Trim5α+ cells did not differ. The CD4 T cell subsets from HIV-1 LTNPs differ from those of HIV-2-infected subjects by higher levels of activation, exhaustion, and SAMHD1 expression that can reflect the distinct patterns of host/virus relationships.- Published
- 2021
- Full Text
- View/download PDF
18. Differential utilization of CD4+ by transmitted/founder and chronic envelope glycoproteins in a MSM HIV-1 subtype B transmission cluster.
- Author
-
Bouvin-Pley M, Leoz M, Roch E, Moreau A, Migraine J, Bellini N, Blake O, Mammano F, Braibant M, Plantier JC, and Brand D
- Subjects
- Humans, Male, CD4-Positive T-Lymphocytes immunology, Glycoproteins genetics, Glycoproteins immunology, Glycoproteins metabolism, HIV Infections immunology, HIV Infections transmission, HIV Infections virology, HIV-1 genetics, HIV-1 immunology, HIV-1 metabolism, Homosexuality, Male, Viral Envelope Proteins genetics, Viral Envelope Proteins immunology, Viral Envelope Proteins metabolism
- Abstract
Objective: HIV-1 transmission leads to a genetic bottleneck, with one or a few variants of the donor quasispecies establishing an infection in the new host. We aimed to characterize this bottleneck in more detail, by comparing the properties of HIV envelope glycoproteins from acute and chronic infections within the particular context of a male-to-male transmission cluster., Design: We compared the genotypic and phenotypic properties of envelope glycoproteins from viral variants derived from five study participants from the same transmission cluster., Methods: We used single-genome amplification to generate a collection of full-length env sequences. We then constructed pseudotyped viruses expressing selected Env variants from the quasispecies infecting each study participant and compared their infectivities and sensitivities to various entry inhibitors., Results: The genotypic analyses confirmed the genetic bottleneck expected after HIV transmission, with a limited number of variants identified in four study participants during acute infection. However, the transmitted sequences harbored no evident common signature and belonged to various genetic lineages. The phenotypic analyses revealed no difference in infectivity, susceptibility to the CCR5 antagonist maraviroc, the fusion inhibitor enfurvitide or type-I interferon between viruses from participants with acute and chronic infections. The key property distinguishing transmitted viruses was a higher resistance to soluble CD4, correlated with greater sensitivity to occupation of the CD4 receptor by the anti-CD4 antibodies LM52 and SK3., Conclusion: These results suggest that envelope glycoproteins from transmitted/founder viruses bind CD4 less efficiently than those of viruses from chronic infections.
- Published
- 2020
- Full Text
- View/download PDF
19. Common evolutionary features of the envelope glycoprotein of HIV-1 in patients belonging to a transmission chain.
- Author
-
Beretta M, Migraine J, Moreau A, Essat A, Goujard C, Chaix ML, Drouin A, Bouvin-Pley M, Meyer L, Barin F, and Braibant M
- Subjects
- Humans, Male, Monocytes metabolism, Monocytes virology, Evolution, Molecular, HIV Infections virology, HIV-1 metabolism, Viral Envelope Proteins metabolism
- Abstract
The diversity of the HIV-1 envelope glycoproteins (Env) is largely a consequence of the pressure exerted by the adaptive immune response to infection. While it was generally assumed that the neutralizing antibody (NAb) response depended mainly on the infected individual, the concept that virus-related factors could be important in inducing this response has recently emerged. Here, we analyzed the influence of the infecting viral strain in shaping NAb responses in four HIV-1 infected subjects belonging to a transmission chain. We also explored the impact of NAb responses on the functional evolution of the viral quasispecies. The four patients developed a strong autologous neutralizing antibody response that drove viral escape and coincided with a parallel evolution of their infecting quasispecies towards increasing infectious properties, increasing susceptibility to T20 and increasing resistance to both CD4 analogs and V3 loop-directed NAbs. This evolution was associated with identical Env sequence changes at several positions in the V3 loop, the fusion peptide and the HR2 domain of gp41. The common evolutionary pattern of Env in different hosts suggests that the capacity of a given Env to adapt to changing environments may be restricted by functional constraints that limit its evolutionary landscape.
- Published
- 2020
- Full Text
- View/download PDF
20. Impact of HIV-1 Diversity on Its Sensitivity to Neutralization.
- Author
-
Stefic K, Bouvin-Pley M, Braibant M, and Barin F
- Abstract
The HIV-1 pandemic remains a major burden on global public health and a vaccine to prevent HIV-1 infection is highly desirable but has not yet been developed. Among the many roadblocks to achieve this goal, the high antigenic diversity of the HIV-1 envelope protein (Env) is one of the most important and challenging to overcome. The recent development of broadly neutralizing antibodies has considerably improved our knowledge on Env structure and its interplay with neutralizing antibodies. This review aims at highlighting how the genetic diversity of HIV-1 thwarts current, and possibly future, vaccine developments. We will focus on the impact of HIV-1 Env diversification on the sensitivity to neutralizing antibodies and the repercussions of this continuous process at a population level.
- Published
- 2019
- Full Text
- View/download PDF
21. HIV-1 antibodies in prevention of transmission.
- Author
-
Barin F and Braibant M
- Subjects
- Animals, HIV Infections immunology, HIV Infections transmission, HIV Infections virology, HIV-1 genetics, Humans, Immunization, Passive, Pre-Exposure Prophylaxis, HIV Antibodies immunology, HIV Infections prevention & control, HIV-1 immunology
- Abstract
Purpose of Review: To present the data that suggest that antibodies to HIV may prevent HIV-1 infection., Recent Findings: Many human monoclonal broadly neutralizing antibodies (bnAbs) have been isolated over the last decade. Numerous experiments of passive immunization in nonhuman primate models have allowed to accumulate strong evidences that bnAbs, opposed to nonneutralizing antibodies, are the best candidates to prevent HIV-1 infection. bnAbs counteract HIV-1 by both blocking the virus at the portal of entry and clearing rapidly viral foci established at distance after dissemination of the virus following infection. Cocktails of bnAbs or modified bi/trispecific antibodies will be necessary to counter the large and evolving antigenic diversity of the HIV-1 species. Two large multicenter phase IIb clinical trials have been initiated. Even if they are not conducted with the most recent and most potent bnAb, the results which are expected in 2022 will inform us on the real potency of bnAbs at preventing HIV-1 acquisition in the real life., Summary: If these trials demonstrate the efficacy of bnAbs, they will open the trail toward new strategies for preexposure prophylaxis, eventually postexposure prophylaxis and prevention of mother-to-child transmission.
- Published
- 2019
- Full Text
- View/download PDF
22. Long-term Physicochemical Stability of Concentrated Solutions of Sodium Valproate in Polypropylene Syringes for Administration in the Intensive Care Unit.
- Author
-
Lardinois B, Baltzis A, Braibant M, Soumoy L, Jamart J, Bihin B, Hecq JD, and Galanti L
- Subjects
- Chromatography, High Pressure Liquid, Drug Storage, Intensive Care Units, Polypropylenes chemistry, Syringes, Valproic Acid
- Abstract
In some situations, drug solutions in higher concentrations are used in intensive care units. The objective of this study was to evaluate the physicochemical stability of concentrated solutions of valproate sodium in polypropylene syringes during 30 days at 5°C ± 3°C. Five syringes of 40 mL containing 20 mg/mL of sodium valproate in 0.9% sodium chloride were prepared and stored at 5°C ± 3°C during 30 days. Immediately after preparation and periodically during the storage, valproate concentrations were measured by high-performance liquid chromatography. Spectrophotometric absorbance at different wavelengths, pH measurement, and microscopic observations were also performed. All solutions were physically stable during the study period storage at 5°C ± 3°C. No color change, turbidity, precipitation, or opacity at visual observation was noticed. No significant pH variations or optic densities were observed. No crystals were seen by microscopic analysis. Concentrations of valproate remained stable during the period of storage. Solutions of sodium valproate 20 mg/mL in syringes of 0.9% sodium chloride were physically and chemically stable for at least 30 days when stored in syringes at 5°C ± 3°C. These solutions may be prepared in advance by a centralized intravenous additive service., (Copyright© by International Journal of Pharmaceutical Compounding, Inc.)
- Published
- 2019
23. Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.
- Author
-
Bouvin-Pley M, Beretta M, Moreau A, Roch E, Essat A, Goujard C, Chaix ML, Moiré N, Martin L, Meyer L, Barin F, and Braibant M
- Subjects
- Antibodies, Neutralizing immunology, Cell Line, Epidemics, HEK293 Cells, HIV Antibodies immunology, HIV Envelope Protein gp120 immunology, HIV Envelope Protein gp120 metabolism, HIV Infections immunology, HIV-1 immunology, Humans, Male, Neutralization Tests methods, Receptors, CCR5 metabolism, Virus Internalization, env Gene Products, Human Immunodeficiency Virus immunology, HIV Infections virology, HIV-1 metabolism, HIV-1 pathogenicity, env Gene Products, Human Immunodeficiency Virus metabolism
- Abstract
We showed previously that during the HIV/AIDS epidemic, the envelope glycoprotein (Env) of HIV-1, and in particular, the gp120 subunit, evolved toward an increased resistance to neutralizing antibodies at a population level. Here, we considered whether the antigenic evolution of the HIV-1 Env is associated with modifications of its functional properties, focusing on cell entry efficacy and interactions with the receptor and coreceptors. We tested the infectivity of a panel of Env-pseudotyped viruses derived from patients infected by subtype B viruses at three periods of the epidemic (1987 to 1991, 1996 to 2000, and 2006 to 2010). Pseudotyped viruses harboring Env from patients infected during the most recent period were approximately 10-fold more infectious in cell culture than those from patients infected at the beginning of the epidemic. This was associated with faster viral entry kinetics: contemporary viruses entered target cells approximately twice as fast as historical viruses. Contemporary viruses were also twice as resistant as historical viruses to the fusion inhibitor enfuvirtide. Resistance to enfuvirtide correlated with a resistance to CCR5 antagonists, suggesting that contemporary viruses expanded their CCR5 usage efficiency. Viruses were equally captured by DC-SIGN, but after binding to DC-SIGN, contemporary viruses infected target cells more efficiently than historical viruses. Thus, we report evidence that the infectious properties of the envelope glycoprotein of HIV-1 increased during the course of the epidemic. It is plausible that these changes affected viral fitness during the transmission process and might have contributed to an increasing virulence of HIV-1. IMPORTANCE Following primary infection by HIV-1, neutralizing antibodies (NAbs) exert selective pressure on the HIV-1 envelope glycoprotein (Env), driving the evolution of the viral population. Previous studies suggested that, as a consequence, Env has evolved at the HIV species level since the start of the epidemic so as to display greater resistance to NAbs. Here, we investigated whether the antigenic evolution of the HIV-1 Env is associated with modifications of its functional properties, focusing on cell entry efficacy and interactions with the receptor and coreceptors. Our data provide evidence that the infectious properties of the HIV-1 Env increased during the course of the epidemic. These changes may have contributed to increasing virulence of HIV-1 and an optimization of transmission between individuals., (Copyright © 2019 American Society for Microbiology.)
- Published
- 2019
- Full Text
- View/download PDF
24. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
- Author
-
Stefic K, Bouvin-Pley M, Essat A, Visdeloup C, Moreau A, Goujard C, Chaix ML, Braibant M, Meyer L, and Barin F
- Subjects
- Adult, Evolution, Molecular, Female, HIV Antibodies pharmacology, HIV-1 classification, HIV-1 genetics, Humans, Immunization, Passive, Male, Middle Aged, Neutralization Tests, Young Adult, env Gene Products, Human Immunodeficiency Virus genetics, Antibodies, Neutralizing pharmacology, HIV Infections virology, HIV-1 drug effects, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Broadly neutralizing antibodies (bnAbs) are promising agents for prevention and/or treatment of HIV-1 infection. However, the diversity among HIV-1 envelope (Env) glycoproteins impacts bnAb potency and breadth. Neutralization data on the CRF02_AG clade are scarce although it is highly prevalent in West Africa and Europe. We assessed the sensitivity to bnAbs of a panel of 33 early transmitted CRF02_AG viruses over a 15-year period of the French epidemic (1997 to 2012). Env pseudotyped CRF02_AG viruses were best neutralized by the CD4 binding site (CD4bs)-directed bnAbs (VRC01, 3BNC117, NIH45-46
G54W , and N6) and the gp41 membrane-proximal external region (MPER)-directed bnAb 10E8 in terms of both potency and breadth. We observed a higher resistance to bnAbs targeting the V1V2-glycan region (PG9 and PGT145) and the V3-glycan region (PGT121 and 10-1074). Combinations were required to achieve full coverage across this subtype. We observed increased resistance to bnAbs targeting the CD4bs linked to the diversification of CRF02_AG Env over the course of the epidemic, a phenomenon which was previously described for subtypes B and C. These data on the sensitivity to bnAbs of CRF02_AG viruses, including only recently transmitted viruses, will inform future passive immunization studies. Considering the drift of the HIV-1 species toward higher resistance to neutralizing antibodies, it appears necessary to keep updating existing panels for evaluation of future vaccine and passive immunization studies. IMPORTANCE Major progress occurred during the last decade leading to the isolation of human monoclonal antibodies, termed broadly neutralizing antibodies (bnAbs) due to their capacity to neutralize various strains of HIV-1. Several clinical trials are under way in order to evaluate their efficacy in preventive or therapeutic strategies. However, no single bnAb is active against 100% of strains. It is important to gather data on the sensitivity to neutralizing antibodies of all genotypes, especially those more widespread in regions where the prevalence of HIV-1 infection is high. Here, we assembled a large panel of clade CRF02_AG viruses, the most frequent genotype circulating in West Africa and the second most frequent found in several European countries. We evaluated their sensitivities to bnAbs, including those most advanced in clinical trials, and looked for the best combinations. In addition, we observed a trend toward increased resistance to bnAbs over the course of the epidemic., (Copyright © 2019 American Society for Microbiology.)- Published
- 2019
- Full Text
- View/download PDF
25. Phenotypic properties of envelope glycoproteins of transmitted HIV-1 variants from patients belonging to transmission chains.
- Author
-
Beretta M, Moreau A, Bouvin-Pley M, Essat A, Goujard C, Chaix ML, Hue S, Meyer L, Barin F, and Braibant M
- Subjects
- Antibodies, Monoclonal immunology, Antibodies, Neutralizing immunology, HIV Antibodies immunology, HIV-1 isolation & purification, Humans, Male, Neutralization Tests, Selection, Genetic, Disease Transmission, Infectious, HIV Infections transmission, HIV Infections virology, HIV-1 growth & development, HIV-1 immunology, Virus Internalization, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Objective: Transmission of HIV-1 involves a bottleneck in which generally a single HIV-1 variant from a diverse viral population in the transmitting partner establishes infection in the new host. It is still unclear to what extent this event is driven by specific properties of the transmitted viruses or the result of a stochastic process. Our study aimed to better characterize this phenomenon and define properties shared by transmitted viruses., Design: We compared antigenic and functional properties of envelope glycoproteins of viral variants found during primary infection in 27 patients belonging to eight transmission chains., Methods: We generated pseudotyped viruses expressing Env variants of the viral quasispecies infecting each patient and compared their sensitivity to neutralization by eight human monoclonal broadly neutralizing antibodies (HuMoNAbs). We also compared their infectious properties by measuring their infectivity and sensitivity to various entry inhibitors., Results: Transmitted viruses from the same transmission chain shared many properties, including similar neutralization profiles, sensitivity to inhibitors, and infectivity, providing evidence that the transmission bottleneck is mainly nonstochastic. Transmitted viruses were CCR5-tropic, sensitive to MVC, and resistant to soluble forms of CD4, irrespective of the cluster to which they belonged. They were also sensitive to HuMoNAbs that target V3, the CD4-binding site, and the MPER region, suggesting that the loss of these epitopes may compromise their capacity to be transmitted., Conclusion: Our data suggest that the transmission bottleneck is governed by selective forces. How these forces confer an advantage to the transmitted virus has yet to be determined.
- Published
- 2018
- Full Text
- View/download PDF
26. Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests.
- Author
-
Favresse J, Lardinois B, Sabor L, Devalet B, Vandepapeliere J, Braibant M, Lessire S, Chatelain B, Jacqmin H, Douxfils J, and Mullier F
- Abstract
The impact of direct oral anticoagulants (DOACs) on laboratory assays used for thrombophilia testing (e.g., antithrombin, protein S, protein C, lupus anticoagulant and activated protein-C resistance) is a well-known issue and may cause false-positive and -negative results. Therefore, the correct interpretation of tests that are performed in patients taking DOACs is mandatory to prevent misclassification and the subsequent clinical consequences. We aimed at evaluating the efficiency of a new and simple procedure (DOAC-Stop®; Haematex Research, Hornsby, Australia) to overcome the effect of all DOACs in real-life settings and to assess the percentage of erroneous results due to the presence of DOACs on thrombophilia screening tests. For this purpose, 135 DOAC-treated patients (38 apixaban, 40 dabigatran, 15 edoxaban, and 42 rivaroxaban) and 20 control patients were enrolled. A significant drop in apixaban, dabigatran, edoxaban, and rivaroxaban plasma concentrations following the DOAC-Stop® treatment was observed (74.8-8.2 ng/mL [ p < 0.0001], 95.9-4.7 ng/mL [ p < 0.0001], 102.1-8.8 ng/mL [ p = 0.001], and 111.3-7.0 ng/mL [ p < 0.0001], respectively). The DOAC-Stop® treatment was mostly effective to overcome the effect of DOACs on PTT-LA, dilute Russell's viper venom time (dRVVT) screen, and dRVVT confirm tests. Using our procedures, false-positive results due to DOACs were observed only with lupus anticoagulant tests (up to 75%) and fell to zero after the DOAC-Stop® procedure, regardless of the DOAC considered. In conclusion, the DOAC-Stop® adsorbent procedure appeared to be an effective and simple way to overcome the interference of DOAC on coagulation tests and should facilitate the interpretation of thrombophilia screening tests in patients taking DOACs.
- Published
- 2018
- Full Text
- View/download PDF
27. Effect of Amino Acid Substitutions Within the V3 Region of HIV-1 CRF01_AE on Interaction with CCR5-Coreceptor.
- Author
-
Hongjaisee S, Braibant M, Barin F, Ngo-Giang-Huong N, Sirirungsi W, and Samleerat T
- Subjects
- Cell Line, HEK293 Cells, Humans, Mutagenesis, Site-Directed methods, Mutation genetics, Virus Internalization, Amino Acid Substitution genetics, HIV Infections metabolism, HIV Infections virology, HIV-1 genetics, Receptors, CCR5 metabolism, env Gene Products, Human Immunodeficiency Virus genetics, env Gene Products, Human Immunodeficiency Virus metabolism
- Abstract
Specific amino acids within the V3 loop of HIV-1 CRF01_AE envelope glycoprotein that are involved in the interaction with CCR5/CXCR4 coreceptors, are not well characterized. We generated V3 mutants using polymerase chain reaction (PCR)-based site-directed mutagenesis of HIV-1 CRF01_AE R5-env plasmids at specific positions. Mutant viruses were produced by env-pseudotyped virus assay, tested for coreceptor usage using U373.R5 and U373.X4 cells, and viral entry was assessed with luciferase activity measurement. All viruses, harboring either single or double mutations, used the CCR5 coreceptor. However, those containing a single substitution at positions 7, 11, 18, and 32 and those with mutations at positions 5/32 and 18/32 had reduced infectivity. Only virus with arginine substitution at position 11 seemed to be involved in CXCR4 coreceptor usage. Our results suggest that some V3 positions may be necessary for the binding to coreceptor, but not for the switch of coreceptor usage.
- Published
- 2017
- Full Text
- View/download PDF
28. Probing the compartmentalization of HIV-1 in the central nervous system through its neutralization properties.
- Author
-
Stefic K, Chaillon A, Bouvin-Pley M, Moreau A, Braibant M, Bastides F, Gras G, Bernard L, and Barin F
- Subjects
- HIV Infections blood, HIV Infections cerebrospinal fluid, HIV Infections virology, HIV-1 immunology, Humans, Longitudinal Studies, Phylogeny, Antibodies, Neutralizing immunology, Central Nervous System virology, HIV-1 isolation & purification
- Abstract
Compartmentalization of HIV-1 has been observed in the cerebrospinal fluid (CSF) of patients at different clinical stages. Considering the low permeability of the blood-brain barrier, we wondered if a reduced selective pressure by neutralizing antibodies (NAb) in the central nervous system (CNS) could favor the evolution of NAb-sensitive viruses in this compartment. Single genome amplification (SGA) was used to sequence full-length HIV-1 envelope variants (453 sequences) from paired CSF and blood plasma samples in 9 subjects infected by HIV variants of various clades and suffering from diverse neurologic disorders. Dynamics of viral evolution were evaluated with a bayesian coalescent approach for individuals with longitudinal samples. Pseudotyped viruses expressing envelope glycoproteins variants representative of the quasi-species present in each compartment were generated, and their sensitivity to autologous neutralization, broadly neutralizing antibodies (bNAbs) and entry inhibitors was assessed. Significant compartmentalization of HIV populations between blood and CSF were detected in 5 out of 9 subjects. Some of the previously described genetic determinants for compartmentalization in the CNS were observed regardless of the HIV-1 clade. There was no difference of sensitivity to autologous neutralization between blood- and CSF-variants, even for subjects with compartmentalization, suggesting that selective pressure by autologous NAb is not the main driver of HIV evolution in the CNS. However, we observed major differences of sensitivity to sCD4 or to at least one bNAb targeting either the N160-V1V2 site, the N332-V3 site or the CD4bs, between blood- and CSF-variants in all cases. In particular, HIV-1 variants present in the CSF were more resistant to bNAbs than their blood counterpart in some cases. Considering the possible migration from CSF to blood, the CNS could be a reservoir of bNAb resistant viruses, an observation that should be considered for immunotherapeutic approaches.
- Published
- 2017
- Full Text
- View/download PDF
29. Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions.
- Author
-
Gasser R, Hamoudi M, Pellicciotta M, Zhou Z, Visdeloup C, Colin P, Braibant M, Lagane B, and Negroni M
- Subjects
- Amides pharmacology, Antigenic Variation, CD4 Antigens metabolism, Evolution, Molecular, Genetic Variation, HIV Envelope Protein gp120 chemistry, HIV Envelope Protein gp120 immunology, HIV Fusion Inhibitors pharmacology, HIV-1 immunology, HIV-1 physiology, Humans, Protein Stability, Quaternary Ammonium Compounds pharmacology, Receptors, CCR5 metabolism, Sequence Alignment, Virus Internalization, HIV Envelope Protein gp120 genetics, HIV-1 genetics, Polymorphism, Genetic
- Abstract
Background: Covariation is an essential process that leads to coevolution of parts of proteins and genomes. In organisms subject to strong selective pressure, coevolution is central to keep the balance between the opposite requirements of antigenic variation and retention of functionality. Being the viral component most exposed to the external environment, the HIV-1 glycoprotein gp120 constitutes the main target of the immune response. Accordingly its more external portions are characterised by extensive sequence heterogeneity fostering constant antigenic variation., Results: We report that a single polymorphism, present at the level of the viral population in the conserved internal region C2, was sufficient to totally abolish Env functionality when introduced in an exogenous genetic context. The prominent defect of the non-functional protein is a block occurring after recognition of the co-receptor CCR5, likely due to an interference with the subsequent conformational changes that lead to membrane fusion. We also report that the presence of compensatory polymorphisms at the level of the external and hypervariable region V3 fully restored the functionality of the protein. The functional revertant presents different antigenic profiles and sensitivity to the entry inhibitor TAK 779., Conclusions: Our data suggest that variable regions, besides harbouring intrinsic extensive antigenic diversity, can also contribute to sequence diversification in more structurally constrained parts of the gp120 by buffering the deleterious effect of polymorphisms, further increasing the genetic flexibility of the protein and the antigenic repertoire of the viral population.
- Published
- 2016
- Full Text
- View/download PDF
30. V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.
- Author
-
Morgand M, Bouvin-Pley M, Plantier JC, Moreau A, Alessandri E, Simon F, Pace CS, Pancera M, Ho DD, Poignard P, Bjorkman PJ, Mouquet H, Nussenzweig MC, Kwong PD, Baty D, Chames P, Braibant M, and Barin F
- Subjects
- Amino Acid Sequence, Antibodies, Monoclonal immunology, CD4 Antigens, CD4 Lymphocyte Count, Chlorofluorocarbons, Methane, Epitopes immunology, Gene Expression Regulation, Viral physiology, HIV Envelope Protein gp120 immunology, HIV Infections virology, HIV-1 classification, HIV-1 genetics, Humans, Molecular Sequence Data, Phylogeny, Recombinant Proteins, env Gene Products, Human Immunodeficiency Virus immunology, Antibodies, Neutralizing immunology, Conserved Sequence, Epitopes genetics, HIV Antibodies immunology, HIV Infections immunology, HIV-1 immunology
- Abstract
Background: Highly potent broadly neutralizing monoclonal antibodies (bNAbs) have been obtained from individuals infected by HIV-1 group M variants. We analyzed the cross-group neutralization potency of these bNAbs toward non-M primary isolates (PI)., Material and Methods: The sensitivity to neutralization was analyzed in a neutralization assay using TZM-bl cells. Twenty-three bNAbs were used, including reagents targeting the CD4-binding site, the N160 glycan-V1/V2 site, the N332 glycan-V3 site, the membrane proximal external region of gp41, and complex epitopes spanning both env subunits. Two bispecific antibodies that combine the inhibitory activity of an anti-CD4 with that of PG9 or PG16 bNAbs were included in the study (PG9-iMab and PG16-iMab)., Results: Cross-group neutralization was observed only with the bNAbs targeting the N160 glycan-V1/V2 site. Four group O PIs, 1 group N PI, and the group P PI were neutralized by PG9 and/or PG16 or PGT145 at low concentrations (0.04-9.39 μg/mL). None of the non-M PIs was neutralized by the bNAbs targeting other regions at the highest concentration tested, except 10E8 that neutralized weakly 2 group N PIs and 35O22 that neutralized 1 group O PI. The bispecific bNAbs neutralized very efficiently all the non-M PIs with IC50 below 1 μg/mL, except 2 group O strains., Conclusion: The N160 glycan-V1/V2 site is the most conserved neutralizing site within the 4 groups of HIV-1. This makes it an interesting target for the development of HIV vaccine immunogens. The corresponding bNAbs may be useful for immunotherapeutic strategies in patients infected by non-M variants.
- Published
- 2016
- Full Text
- View/download PDF
31. The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?
- Author
-
Braibant M and Barin F
- Subjects
- Animals, Antibodies, Monoclonal immunology, Antibodies, Monoclonal therapeutic use, Antibodies, Neutralizing immunology, Biomedical Research trends, Disease Models, Animal, HIV Antibodies immunology, HIV Infections immunology, Humans, Immunization, Passive, Macaca, Antibodies, Neutralizing therapeutic use, Disease Transmission, Infectious prevention & control, HIV Antibodies therapeutic use, HIV Infections prevention & control, HIV-1 immunology
- Abstract
In most viral infections, protection through existing vaccines is linked to the presence of vaccine-induced neutralizing antibodies (NAbs). However, more than 30 years after the identification of AIDS, the design of an immunogen able to induce antibodies that would neutralize the highly diverse HIV-1 variants remains one of the most puzzling challenges of the human microbiology. The role of antibodies in protection against HIV-1 can be studied in a natural situation that is the mother-to-child transmission (MTCT) context. Indeed, at least at the end of pregnancy, maternal antibodies of the IgG class are passively transferred to the fetus protecting the neonate from new infections during the first weeks or months of life. During the last few years, strong data, presented in this review, have suggested that some NAbs might confer protection toward neonatal HIV-1 infection. In cases of transmission, it has been shown that the viral population that is transmitted from the mother to the infant is usually homogeneous, genetically restricted and resistant to the maternal HIV-1-specific antibodies. Although the breath of neutralization was not associated with protection, it has not been excluded that NAbs toward specific HIV-1 strains might be associated with a lower rate of MTCT. A better identification of the antibody specificities that could mediate protection toward MTCT of HIV-1 would provide important insights into the antibody responses that would be useful for vaccine development. The most convincing data suggesting that NAbs might confer protection against HIV-1 infection have been obtained by experiments of passive immunization of newborn macaques with the first generation of human monoclonal broadly neutralizing antibodies (HuMoNAbs). However, these studies, which included only a few selected subtype B challenge viruses, provide data limited to protection against a very restricted number of isolates and therefore have limitations in addressing the hypervariability of HIV-1. The recent identification of highly potent second-generation cross-clade HuMoNAbs provides a new opportunity to evaluate the efficacy of passive immunization to prevent MTCT of HIV-1.
- Published
- 2013
- Full Text
- View/download PDF
32. Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups.
- Author
-
Braibant M, Gong EY, Plantier JC, Moreau T, Alessandri E, Simon F, and Barin F
- Subjects
- HIV-1 classification, HIV-1 isolation & purification, Humans, Models, Theoretical, Neutralization Tests methods, Antibodies, Neutralizing immunology, Epitopes immunology, HIV Antibodies immunology, HIV Infections immunology, HIV-1 immunology
- Abstract
Objective: HIV-1 has been classified into four groups: M, N, O and P. The aim of this study was to revisit the cross-group neutralization using a highly diverse panel of primary isolates., Design: The panel of viruses included nine HIV-1 group O primary isolates, one recombinant M/O primary isolate, one group N primary isolates, one group P primary isolate, two group M (subtype B) primary isolates and the HIV-1 group M adapted strain MN., Methods: All the viruses were tested for neutralization in TZM-bl cells, using sera issued from patients infected by viruses of group M (n = 11), O (n = 12) and P (n = 1), and a panel of nine human monoclonal broadly neutralizing antibodies (HuMo bNAbs)., Results: Although the primary isolates displayed a wide spectrum of sensitivity to neutralization by the human sera, cross-group neutralization was clearly observed. In contrast, the bNAbs did not show any cross-group neutralization, except PG9 and PG16. Interestingly, the group N prototype strain YBF30 was highly sensitive to neutralization by PG9 (IC50: 0.28 μg/ml) and PG16 (IC50: < 0.12 μg/ml). The interaction between PG9 and key residues of YBF30 was confirmed by molecular modeling., Conclusion: The conservation of the PG9 and PG16 epitopes within groups M and N provides an argument for their relevance as components of a potentially efficient HIV vaccine immunogen.
- Published
- 2013
- Full Text
- View/download PDF
33. Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic.
- Author
-
Bouvin-Pley M, Morgand M, Moreau A, Jestin P, Simonnet C, Tran L, Goujard C, Meyer L, Barin F, and Braibant M
- Subjects
- Antibodies, Monoclonal metabolism, Antibody Specificity, Antigens, Viral biosynthesis, Antigens, Viral genetics, Antigens, Viral metabolism, Cohort Studies, Epidemiological Monitoring, Epitopes genetics, France epidemiology, HIV Infections epidemiology, HIV Infections transmission, HIV-1 genetics, HIV-1 metabolism, Humans, Immunity, Humoral, Immunogenetic Phenomena, Membrane Glycoproteins antagonists & inhibitors, Membrane Glycoproteins genetics, Membrane Glycoproteins metabolism, Phylogeny, RNA, Viral blood, RNA, Viral metabolism, Viral Envelope Proteins antagonists & inhibitors, Viral Envelope Proteins genetics, Viral Envelope Proteins metabolism, Antibodies, Neutralizing metabolism, Epidemics, Genetic Drift, HIV Infections immunology, HIV Infections virology, HIV-1 immunology
- Abstract
We compared the neutralization sensitivity of early/transmitted HIV-1 variants from patients infected by subtype B viruses at 3 periods of the epidemic (1987-1991, 1996-2000, 2006-2010). Infectious pseudotyped viruses expressing envelope glycoproteins representative of the viral quasi-species infecting each patient were tested for sensitivity to neutralization by pools of sera from HIV-1 chronically infected patients and by an updated panel of 13 human monoclonal neutralizing antibodies (HuMoNAbs). A progressive significantly enhanced resistance to neutralization was observed over calendar time, by both human sera and most of the HuMoNAbs tested (b12, VRC01, VRC03, NIH45-46(G54W), PG9, PG16, PGT121, PGT128, PGT145). Despite this evolution, a combination of two HuMoNAbs (NIH45-46(G54W) and PGT128) still would efficiently neutralize the most contemporary transmitted variants. In addition, we observed a significant reduction of the heterologous neutralizing activity of sera from individuals infected most recently (2003-2007) compared to patients infected earlier (1987-1991), suggesting that the increasing resistance of the HIV species to neutralization over time coincided with a decreased immunogenicity. These data provide evidence for an ongoing adaptation of the HIV-1 species to the humoral immunity of the human population, which may add an additional obstacle to the design of an efficient HIV-1 vaccine.
- Published
- 2013
- Full Text
- View/download PDF
34. The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1.
- Author
-
Chaillon A, Wack T, Braibant M, Mandelbrot L, Blanche S, Warszawski J, and Barin F
- Subjects
- Adult, Case-Control Studies, Cohort Studies, Female, HIV Antibodies immunology, HIV Infections immunology, Humans, Infant, Newborn, Infectious Disease Transmission, Vertical, Male, Maternal Exposure, Mothers, Pregnancy, Pregnancy Complications, Infectious immunology, Antibodies, Neutralizing chemistry, HIV Infections transmission, HIV-1 metabolism, Neutralization Tests methods, Pregnancy Complications, Infectious diagnosis
- Abstract
It has been hypothesized that neutralizing antibodies (NAbs) should have broad specificity to be effective in protection against diverse HIV-1 variants. The mother-to-child transmission model of HIV-1 provides the opportunity to examine whether the breadth of maternal NAbs is associated with protection of infants from infection. Samples were obtained at delivery from 57 transmitting mothers (T) matched with 57 nontransmitting mothers (NT) enrolled in the multicenter French perinatal cohort (ANRS EPF CO1) between 1990 and 1996. Sixty-eight (59.6%) and 46 (40.4%) women were infected by B and non-B viruses, respectively. Neutralization assays were carried out with TZM-bl cells, using a panel of 10 primary isolates of 6 clades (A, B, C, F, CRF01_AE, and CRF02_AG), selected for their moderate or low sensitivity to neutralization. Neutralization breadths were not statistically different between T and NT mothers. However, a few statistically significant differences were observed, with higher frequencies or titers of NAbs toward several individual strains for NT mothers when the clade B-infected or non-clade B-infected mothers were analyzed separately. Our study confirms that the breadth of maternal NAbs is not associated with protection of infants from infection.
- Published
- 2012
- Full Text
- View/download PDF
35. Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.
- Author
-
Thenin S, Roch E, Samleerat T, Moreau T, Chaillon A, Moreau A, Barin F, and Braibant M
- Subjects
- Amino Acid Substitution, Antibodies, Monoclonal immunology, DNA Mutational Analysis, HIV-1 genetics, HIV-1 isolation & purification, Humans, Molecular Sequence Data, Mutagenesis, Site-Directed, Mutant Proteins genetics, Mutant Proteins immunology, Neutralization Tests, RNA, Viral genetics, Sequence Analysis, DNA, Antibodies, Neutralizing immunology, HIV Antibodies immunology, HIV Infections virology, HIV-1 immunology, Mutation, Missense, env Gene Products, Human Immunodeficiency Virus genetics, env Gene Products, Human Immunodeficiency Virus immunology
- Abstract
The recently described anti-human immunodeficiency virus type 1 (HIV-1) human mAb PG9 and PG16 are cross-clade broadly neutralizing. Therefore, it can be postulated that the targeted epitope(s) are highly conserved among variants of the entire group M. We analysed the sensitivity to PG9 and PG16 of pseudotyped viruses carrying envelope glycoproteins from the viral quasispecies of three HIV-1 clade CRF01_AE-infected patients. The broad heterogeneity in sensitivity to PG9 and PG16, despite closely genetically related envelope glycoproteins issued from single individuals, allowed us to identify two gp120 cross-clade conserved residues, a lysine at position 168 in the V2 loop and an isoleucine at position 215 in the C2 region, whose substitutions were associated with resistance to PG9 and PG16. By site-directed mutagenesis, we confirmed both in clades B and CRF01_AE that the substitutions K168E and I215M have a major impact on PG9 and PG16 neutralization sensitivity of pseudotyped viruses.
- Published
- 2012
- Full Text
- View/download PDF
36. Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties.
- Author
-
Thenin S, Samleerat T, Tavernier E, Ngo-Giang-Huong N, Jourdain G, Lallemant M, Barin F, and Braibant M
- Subjects
- Adult, Cell Line, Female, Genetic Variation, HIV Antibodies immunology, HIV Infections immunology, HIV Infections transmission, HIV-1 classification, HIV-1 genetics, HIV-1 isolation & purification, Humans, Infant, Male, Molecular Sequence Data, Neutralization Tests, Phylogeny, HIV Envelope Protein gp120 genetics, HIV Envelope Protein gp120 immunology, HIV Infections virology, HIV-1 immunology, Infectious Disease Transmission, Vertical
- Abstract
Several studies have shown that the early virus population present in HIV-1 infected infants usually is homogeneous when compared to the highly diversified viral population present at delivery in their mothers. We explored the antigenic and functional properties of pseudotyped viruses expressing gp120 encoded by env clones issued from four mother-infant pairs infected by CRF01_AE viruses. We compared their sensitivity to neutralization and to entry inhibitors, their infectivity levels and the Env processing and incorporation levels. We found that both transmitted viruses present in infants and the variants present in their chronically infected mothers display a wide spectrum of biological properties that could not distinguish between them. In contrast, we found that all the transmitted viruses in the infants were more sensitive to neutralization by PG9 and PG16 than the maternal variants, an observation that may have implications for the development of prophylactic strategies to prevent mother-to-child transmission., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
37. Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.
- Author
-
Chaillon A, Braibant M, Hué S, Bencharif S, Enard D, Moreau A, Samri A, Agut H, and Barin F
- Subjects
- Amino Acid Sequence, Analysis of Variance, Bayes Theorem, Evolution, Molecular, HIV Envelope Protein gp120 immunology, HIV Infections blood, HIV Infections immunology, HIV-1 immunology, Humans, Likelihood Functions, Markov Chains, Models, Genetic, Monte Carlo Method, Phylogeny, Selection, Genetic, Sensitivity and Specificity, Sequence Analysis, DNA, Survivors, Antibodies, Neutralizing blood, HIV Envelope Protein gp120 genetics, HIV Infections virology, HIV-1 genetics
- Abstract
Background: The evolution of HIV-1 and its immune escape to autologous neutralizing antibodies (Nabs) during the acute/early phases of infection have been analyzed in depth in many studies. In contrast, little is known about neither the long-term evolution of the virus in patients who developed broadly Nabs (bNabs) or the mechanism of escape in presence of these bNabs., Results: We have studied the viral population infecting a long term non progressor HIV-1 infected patient who had developed broadly neutralizing antibodies toward all tier 2/3 viruses (6 clades) tested, 9 years after infection, and was then followed up over 7 years. The autologous neutralization titers of the sequential sera toward env variants representative of the viral population significantly increased during the follow-up period. The most resistant pseudotyped virus was identified at the last visit suggesting that it represented a late emerging escape variant. We identified 5 amino acids substitutions that appeared associated with escape to broadly neutralizing antibodies. They were V319I/S, R/K355T, R/W429G, Q460E and G/T463E, in V3, C3 and V5 regions., Conclusion: This study showed that HIV-1 may continue to evolve in presence of both broadly neutralizing antibodies and increasing autologous neutralizing activity more than 10 years post-infection.
- Published
- 2012
- Full Text
- View/download PDF
38. The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12.
- Author
-
Chaillon A, Braibant M, Moreau T, Thenin S, Moreau A, Autran B, and Barin F
- Subjects
- HIV Envelope Protein gp120 genetics, HIV-1 genetics, Humans, Models, Molecular, Molecular Sequence Data, Mutagenesis, Site-Directed, Mutant Proteins genetics, Mutant Proteins immunology, Neutralization Tests, Recombination, Genetic, Sequence Analysis, DNA, Antibodies, Neutralizing immunology, HIV Antibodies immunology, HIV Envelope Protein gp120 immunology, HIV-1 immunology
- Abstract
The broadly neutralizing human monoclonal antibody 2G12 binds to a carbohydrate-dependent epitope involving three major potential N-linked glycosylation sites (PNGS) of gp120 (N295, N332, and N392). Through analysis of the sensitivity to 2G12 of pseudotyped viruses carrying envelope proteins from HIV-1 clade B-infected long-term nonprogressors, we selected two naturally occurring env clones with opposite sensitivities to 2G12, albeit harboring the 3 particular PNGS known to be essential for 2G12 binding (N295, N332, and N392). The resistant clone presented a long and potentially heavily glycosylated V1V2 loop and an additional PNGS (N302) in the V3 loop. The sensitive clone harbored a short V1V2 loop and lacked the PNGS at N302. We created chimeric envelope genes by swapping the V1V2 domains of the two env clones. The influence of N302 on 2G12 sensitivity was assessed by PCR-based site-directed mutagenesis. Both the exchange of the V1V2 domain and the introduction of the PNGS at N302 on the 2G12-sensitive clone induced a significant decrease in sensitivity to 2G12. In contrast, the reverse V1V2 exchange and the removal of the PNGS at N302 on the 2G12-resistant clone increased sensitivity to 2G12, confirming the influence of these regions on 2G12 sensitivity. Our results, supported by a molecular-modeling study, suggest that both the V1V2 loop and an additional PNGS in V3 might limit access to the 2G12 epitope.
- Published
- 2011
- Full Text
- View/download PDF
39. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine.
- Author
-
Papagno L, Alter G, Assoumou L, Murphy RL, Garcia F, Clotet B, Larsen M, Braibant M, Marcelin AG, Costagliola D, Altfeld M, Katlama C, and Autran B
- Subjects
- Antibodies, Neutralizing immunology, Canarypox virus immunology, Double-Blind Method, HIV Infections therapy, HIV Infections virology, Humans, RNA, Viral drug effects, Viral Load, Viral Vaccines immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, HIV Infections immunology, HIV-1, RNA, Viral immunology, Viral Vaccines therapeutic use
- Abstract
Background: HIV-specific T-cell-based vaccines have been extensively studied in both prevention and therapeutic settings, with most studies failing to show benefit, and some suggesting harm. We previously performed a multicenter, double-blind, placebo-controlled phase II clinical trial in which 65 antiretroviral-treated patients were randomized to receive an HIV-1 recombinant canarypox vaccine (vCP1452) or placebo, followed by analytical treatment interruption. Patients exposed to vaccine had higher levels of viral replication and more rapid time to treatment resumption., Objective: In the present study we report the results from extensive immunological investigations to test whether the preferential expansion of HIV-specific CD4(+), rather than CD8(+) T cells, could account for these unexpected results., Methods: Polychromatic flow cytometry was used to characterize the functional and phenotypic profile of antigen-specific CD8(+) and CD4(+) T cells induced by the immunization., Results: We found a significant increase in HIV-specific CD4(+) T cells producing IFN-γ and IL-2 in the 4 injections arm compared to the placebo arm following vaccination. In contrast, no difference was observed following vaccination in the phenotype and functional capacity within the CD8(+) T-cell compartment. Neither HLA biases, nor immune hyper-activation, or Env-specific facilitating antibodies were associated with the enhanced virus rebound observed in vaccinees., Conclusion: Our data suggest that a vaccine-induced transient activation of HIV-specific CD4(+) but not CD8(+) T cells may have a detrimental effect on HIV outcomes. These findings may provide a mechanistic basis for higher rates of HIV acquisition or replication that have been associated with some T-cell vaccines.
- Published
- 2011
- Full Text
- View/download PDF
40. Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain.
- Author
-
Braibant M, Xie J, Samri A, Agut H, Autran B, and Barin F
- Subjects
- Amino Acid Sequence, Base Sequence, Gene Expression Regulation physiology, HLA-B Antigens genetics, Humans, Male, Middle Aged, Molecular Sequence Data, Phylogeny, Time Factors, nef Gene Products, Human Immunodeficiency Virus chemistry, nef Gene Products, Human Immunodeficiency Virus metabolism, HIV Infections virology, HIV Long-Term Survivors, HIV-1 genetics, HLA-B Antigens metabolism, Superinfection virology, nef Gene Products, Human Immunodeficiency Virus genetics
- Abstract
We describe the case of an HLA-B57-positive long-term nonprogressor in whom we previously showed that PBMCs accumulated HIV-1 subtype B proviruses defective in the env gene. After more than 10 years of control of infection, plasma viremia increased progressively, with a concomitant loss of CD4(+) T cells. By phylogenetic analyses of env, nef, vif, and gag sequences obtained at different time points, we suggest here that this patient was initially infected by a putatively attenuated nef-defective variant and that loss of control was due to superinfection with a fully competent virus belonging to the same clade B. At the time of superinfection, its plasma was unable to efficiently neutralize the superinfecting virus and moderate Gag-specific CD8(+) T-cell responses were observed. This suggests the limited capacity of even a long-lasting natural infection with a nef-deficient HIV-1 strain to elicit immune responses able to prevent and control superinfection with a virus of the same clade., (Copyright 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
41. Maternal neutralizing antibodies against a CRF01_AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission.
- Author
-
Samleerat T, Thenin S, Jourdain G, Ngo-Giang-Huong N, Moreau A, Leechanachai P, Ithisuknanth J, Pagdi K, Wannarit P, Sangsawang S, Lallemant M, Barin F, and Braibant M
- Subjects
- Adult, Amino Acid Sequence, Antibody Specificity, Female, HIV Antibodies immunology, HIV Envelope Protein gp120 chemistry, HIV Envelope Protein gp120 immunology, Humans, Molecular Sequence Data, Neutralization Tests, Pregnancy, Pregnancy Complications, Infectious virology, Protein Structure, Tertiary genetics, Sequence Alignment, Thailand, HIV Antibodies blood, HIV Infections blood, HIV Infections transmission, HIV-1 immunology, Infectious Disease Transmission, Vertical, Pregnancy Complications, Infectious blood
- Abstract
Mother-to-child transmission (MTCT) of HIV-1 provides a model for studying the role of passively acquired antibodies in preventing HIV infection. We determined the titers of neutralizing antibodies (NAbs) against six primary isolates of clades B and CRF01_AE in sera from 45 transmitting and 45 nontransmitting mothers matched for the main independent factors associated with MTCT in Thailand. A lower risk of MTCT, particularly for intrapartum transmission, was associated only with higher NAb titers against the CRF01_AE strain, MBA. The envelope glycoprotein of this strain showed an unusually long V2 domain of 63 amino acids, encoding six potential N-linked glycosylation sites. We provided experimental data indicating that the extended V2 domain contributed to the higher level of resistance to neutralization by mothers' sera in this strain. Taken together the data suggest that some primary isolates with specific properties may be useful indicators for identifying protective antibodies.
- Published
- 2009
- Full Text
- View/download PDF
42. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
- Author
-
Martinez V, Diemert MC, Braibant M, Potard V, Charuel JL, Barin F, Costagliola D, Caumes E, Clauvel JP, Autran B, and Musset L
- Subjects
- Adolescent, Adult, Aged, Antibodies, Anticardiolipin blood, B-Lymphocytes immunology, CD4 Lymphocyte Count, CD8-Positive T-Lymphocytes immunology, Female, HIV Antibodies blood, Humans, Immunoglobulin G blood, Immunoglobulin G immunology, Lymphocyte Activation, Male, Middle Aged, Viral Load, Antibodies, Anticardiolipin immunology, DNA, Viral biosynthesis, HIV Antibodies immunology, HIV Infections immunology
- Abstract
Background: The demonstration of in vitro cardiolipin reactivity with 2 human immunodeficiency virus (HIV)-specific, broadly neutralizing antibodies (2F5 and 4E10) has prompted reevaluation of autoimmune manifestations in HIV infection., Methods: We evaluated autoantibodies, particularly anticardiolipin (aCL), in 67 untreated, asymptomatic, HIV-infected individuals with slow progression of HIV disease and their correlation with 2F5-, 4E10-, b12-, and 2G12-like antibodies directed against epitopes involved in broad neutralization, as well as their correlation with immune activation and virological and clinical indicators. Fifty individuals with chronic HIV infection and standard disease progression were control patients., Results: The majority of the study patients with slow progression of HIV disease were men (78%); their median age was 37 years, their median CD4+ cell count was 672 cells/mL, and their median plasma HIV load was 6200 copies/mL. The majority of the control patients were also men (76%), and most (62%) were receiving highly active antiretroviral therapy; their median age was 43 years, their median CD4+ cell count was 202 cells/mL, and their median plasma HIV load was 2265 copies/mL. aCL immunoglobulin G was detected at similar levels in 49% of patients with slow progression of HIV disease and in 58% of control patients. Viral load was positively associated with aCL in both groups (P < .001), independent of CD4+ cell counts. In patients with slow progression of HIV disease, aCL levels were also correlated with plasma HIV load and cell-associated DNA level (r = 0.486 and r = 0.516, respectively; P < .001), with the proportion of activated CD4+ cells, human leukocyte antigen-DR+ cells (r = 0.445; P = or < .001) but not activated CD8+ T cells, and with the level of B cell activation (quantified by soluble CD23; r = 0.354; P = .007). The level of aCL antibodies was associated with the level of antibodies to the membrane proximal region of gp41 (P = .003)., Conclusion: aCL is frequently detected in HIV-infected patients, regardless of disease stage, and is strongly linked with the level of viral replication, the level of CD4+ T and B cell activation, and the level of antibodies to the membrane proximal external region of gp41, independent of CD4+ cell deficiency.
- Published
- 2009
- Full Text
- View/download PDF
43. Characteristics of the env genes of HIV type 1 quasispecies in long-term nonprogressors with broadly neutralizing antibodies.
- Author
-
Braibant M, Agut H, Rouzioux C, Costagliola D, Autran B, and Barin F
- Subjects
- Amino Acid Sequence, Cloning, Molecular, DNA, Viral chemistry, DNA, Viral genetics, France epidemiology, Genetic Variation, HIV Antibodies immunology, HIV Envelope Protein gp120 genetics, HIV Infections blood, HIV Long-Term Survivors, HIV Seropositivity, HIV-1 classification, HIV-1 immunology, Humans, Molecular Sequence Data, Neutralization Tests, Phylogeny, Sequence Analysis, DNA, Sequence Homology, Amino Acid, HIV Antibodies blood, HIV Infections virology, HIV-1 genetics, env Gene Products, Human Immunodeficiency Virus genetics
- Abstract
Primary isolates of different subtypes of HIV-1 can be neutralized in vitro by the broadly neutralizing antibodies (NAbs) found in the sera of a small number of HIV-1-infected patients. This broad response is most frequent in long-term nonprogressors (LTNPs). We investigated whether the presence of NAbs in the sera of some LTNPs was associated with particular properties of the envelope glycoproteins of the variants found in these patients. Toward that aim, 147 env gene fragments (encoding almost the entire gp120) amplified from the proviral DNA of 5 LTNPs who developed broadly NAbs (NAb+) and of 4 LTNPs who did not develop such broadly NAbs (NAb-) were cloned, sequenced, and compared. We found that the development of broadly NAbs was associated with high viral loads, greater diversity in the gp120 of the viruses infecting these patients, and longer V1 sequences and additional N-gly sites in V1. In addition, a higher proportion of defective clones was found among the env genes of NAb- patients (25% to 93%)-particularly those with lower viral loads and low levels of env diversity-than among those of NAb+ patients (7% to 19%).
- Published
- 2008
- Full Text
- View/download PDF
44. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
- Author
-
Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, Autran B, and Barin F
- Subjects
- Antibody Specificity, Antigen-Antibody Reactions, Case-Control Studies, Enzyme-Linked Immunosorbent Assay methods, HIV Envelope Protein gp120 immunology, HIV Envelope Protein gp41 immunology, Humans, Neutralization Tests, Statistics, Nonparametric, HIV Antibodies blood, HIV Infections immunology, HIV Long-Term Survivors, HIV-1 immunology, Immunodominant Epitopes immunology
- Abstract
Objective: Previous studies have shown that broadly neutralizing antibodies (NAb) are more frequent in long-term non-progressors (LTNP) than in other HIV-1 infected patients, but nothing is known about the envelope regions targeted by these broadly NAb. We investigated whether the breadth of neutralizing activity of sera was associated with the presence of specific antibodies (2F5- and/or 4E10-like, b12-like or 2G12-like antibodies) directed against conserved epitopes known to be involved in broad neutralization., Methods: We assessed the ability of sera from 67 LTNP of the French ANRS cohort (ANRS CO15) to neutralize four heterologous primary isolates of four various clades. Competitive and non-competitive ELISA were developed for the specific comparison of levels of antibodies against these specific epitopes in neutralizing and non-neutralizing sera from LTNP., Results: We found that higher 2G12-like antibody levels were significantly associated with the broadest neutralizing activity in sera from LTNP. Levels of 2G12-like antibodies were higher in the sera that neutralized the four isolates than in the others, with a median of 5.7 microg/ml [interquartile range (IQR), 2.7-9.3 microg/ml] versus 2.3 microg/ml (IQR, 1.1-3.9 microg/ml) (Mann-Whitney test, P = 0.03). Levels of antibodies against the other targeted envelope epitopes did not differ significantly between broadly and non-broadly neutralizing sera., Conclusion: These results suggest that the antigenicity of the "silent face" of gp120 that exposes the 2G12 epitope should be analysed in more detail, to find ways to induce broadly neutralizing antibodies.
- Published
- 2006
- Full Text
- View/download PDF
45. Structural and functional study of the phenicol-specific efflux pump FloR belonging to the major facilitator superfamily.
- Author
-
Braibant M, Chevalier J, Chaslus-Dancla E, Pagès JM, and Cloeckaert A
- Subjects
- Amino Acid Sequence, Bacterial Proteins genetics, Chloramphenicol Resistance, Computer Simulation, Escherichia coli metabolism, Escherichia coli Proteins, Molecular Sequence Data, Salmonella typhimurium genetics, Salmonella typhimurium metabolism, Structure-Activity Relationship, Anti-Bacterial Agents pharmacology, Bacterial Proteins chemistry, Bacterial Proteins metabolism, Chloramphenicol pharmacology, Drug Resistance, Bacterial, Salmonella typhimurium drug effects, Thiamphenicol analogs & derivatives, Thiamphenicol pharmacology
- Abstract
The florfenicol-chloramphenicol resistance gene floR from Salmonella enterica was previously identified and postulated to belong to the major facilitator (MF) superfamily of drug exporters. Here, we confirmed a computer-predicted transmembrane topological model of FloR, using the phoA gene fusion method, and classified this protein in the DHA12 family (containing 12 transmembrane domains) of MF efflux transporters. We also showed that FloR is a transporter specific for structurally associated phenicol drugs (chloramphenicol, florfenicol, thiamphenicol) which utilizes the proton motive force to energize an active efflux mechanism. By site-directed mutagenesis of specific charged residues belonging to putative transmembrane segments (TMS), two residues essential for active efflux function, D23 in TMS1 and R109 in TMS4, were identified. Of these, the acidic residue D23 seems to participate directly in the affinity pocket involved in phenicol derivative recognition. A third residue, E283 in TMS9, seems to be necessary for correct membrane folding of the transporter.
- Published
- 2005
- Full Text
- View/download PDF
46. Mycobacterium tuberculosis with disruption in genes encoding the phosphate binding proteins PstS1 and PstS2 is deficient in phosphate uptake and demonstrates reduced in vivo virulence.
- Author
-
Peirs P, Lefèvre P, Boarbi S, Wang XM, Denis O, Braibant M, Pethe K, Locht C, Huygen K, and Content J
- Subjects
- Animals, Bacterial Proteins genetics, Bacterial Proteins metabolism, Culture Media, Humans, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mycobacterium tuberculosis genetics, Mycobacterium tuberculosis metabolism, Phosphate-Binding Proteins metabolism, Tuberculosis physiopathology, Virulence, Gene Deletion, Mycobacterium tuberculosis growth & development, Mycobacterium tuberculosis pathogenicity, Phosphate-Binding Proteins genetics, Phosphates metabolism, Tuberculosis microbiology
- Abstract
By measuring phosphate uptake by Mycobacterium tuberculosis strains with the pstS1 and pstS2 genes genetically inactivated, we showed that these pstS genes encode high-affinity phosphate binding proteins. In a mouse infection model, both mutants were attenuated in virulence, suggesting that M. tuberculosis encounters limiting phosphate concentrations during its intracellular life span.
- Published
- 2005
- Full Text
- View/download PDF
47. Functional characterization of Brucella melitensis NorMI, an efflux pump belonging to the multidrug and toxic compound extrusion family.
- Author
-
Braibant M, Guilloteau L, and Zygmunt MS
- Subjects
- Biological Transport, Active, Brucella melitensis metabolism, Drug Resistance, Multiple, Bacterial genetics, Energy Metabolism physiology, Escherichia coli drug effects, Genome, Bacterial, Kinetics, Molecular Sequence Data, Anti-Bacterial Agents metabolism, Anti-Bacterial Agents pharmacology, Brucella melitensis genetics, Membrane Transport Proteins metabolism
- Abstract
Two putative proteins (NorMI and NorMII) similar to the multidrug efflux protein NorM of Vibrio parahaemolyticus are encoded by the Brucella melitensis 16 M genome. We show that a drug-hypersusceptible Escherichia coli strain overexpressing NorMI displays increased resistance to norfloxacin, ciprofloxacin, gentamicin, tetraphenylphosphonium ion, acriflavine, and berberine. This elevated resistance was proven to be mediated by an energy-dependent efflux mechanism. NorMI belongs to the multidrug and toxic compound extrusion family and is the first multidrug efflux protein identified in Brucella spp.
- Published
- 2002
- Full Text
- View/download PDF
48. The cell surface associated phosphatase activity of Mycobacterium bovis BCG is not regulated by environmental inorganic phosphate.
- Author
-
Braibant M and Content J
- Subjects
- Acid Phosphatase biosynthesis, Alkaline Phosphatase biosynthesis, Cell Membrane enzymology, Culture Media, Enzyme Induction, Hydrogen-Ion Concentration, Mycobacterium bovis growth & development, Acid Phosphatase metabolism, Alkaline Phosphatase metabolism, Mycobacterium bovis enzymology, Phosphates metabolism
- Abstract
Non-specific phosphomonoesterase activities (alkaline phosphatase (EC 3.1.3.1) and acid phosphatase (EC 3.1.3.2)) were examined at the cell surface of Mycobacterium bovis BCG. Using p-nitrophenylphosphate as the substrate, peaks of phosphatase activity were detected at pH 6.0, pH 10.0 and pH 12.0, suggesting the presence of one acid phosphatase and two alkaline phosphatases with distinct optimum pH values. Contrary to the situation observed in several other microorganisms, the expression of these enzymes is not regulated by the environmental inorganic phosphate concentration.
- Published
- 2001
- Full Text
- View/download PDF
49. The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis.
- Author
-
Braibant M, Gilot P, and Content J
- Subjects
- ATP-Binding Cassette Transporters genetics, Amino Acid Sequence, Amino Acids metabolism, Anions metabolism, Anti-Bacterial Agents metabolism, Artificial Gene Fusion, Bacterial Proteins genetics, Binding Sites, Carbohydrate Metabolism, Genome, Bacterial, Iron metabolism, Macrolides metabolism, Membranes metabolism, Molecular Sequence Data, Mycobacterium tuberculosis genetics, Nucleotides metabolism, Peptides metabolism, ATP-Binding Cassette Transporters metabolism, Bacterial Proteins metabolism, Mycobacterium tuberculosis metabolism
- Abstract
We have undertaken the inventory and assembly of the typical subunits of the ABC transporters encoded by the complete genome of Mycobacterium tuberculosis. These subunits, i.e. the nucleotide binding domains (NBDs), the membrane-spanning domains (MSDs) and the substrate binding proteins (SBPs), were identified on the basis of their characteristic stretches of amino acids and/or conserved structure. A total of 45 NBDs present in 38 proteins, of 47 MSDs present in 44 proteins and of 15 SBPs were found to be encoded by M. tuberculosis. Analysis of transcriptional clusters and searches of homology between the identified subunits of the transporters and proteins characterized in other organisms allowed the reconstitution of at least 26 complete (including at least one NBD and one MSD) and 11 incomplete ABC transporters. Sixteen of them were unambiguously classified as importers whereas 21 were presumed to be exporters. By searches of homology with already known transporters from other organisms, potential substrates (peptides, macrolides, carbohydrates, multidrugs, antibiotics, iron, anions) could be attributed to 30 of the ABC transporters identified in M. tuberculosis. The ABC transporters have been further classified in nine different sub-families according to a tree obtained from the clustering of their NBDs. Contrary to Escherichia coli and similarly to Bacillus subtilis, there is an equal representation of extruders and importers. Many exporters were found to be potentially implicated in the transport of drugs, probably contributing to the resistance of M. tuberculosis to many antibiotics. Interestingly, a transporter (absent in E. coli and in B. subtilis) potentially implicated in the export of a factor required for the bacterial attachment to the eukaryotic host cells was also identified. In comparison to E. coli and B. subtilis, there is an under-representation of the importers (with the exception of the phosphate importers) in M. tuberculosis. This may reflect the capacity of this bacterium to synthesize many essential compounds and to grow in the presence of few external nutrients. The genes encoding the ABC transporters occupy about 2.5% of the genome of M. tuberculosis.
- Published
- 2000
- Full Text
- View/download PDF
50. Characterization of a Mycobacterium bovis BCG insertion sequence related to the IS21 family.
- Author
-
Lefèvre P, Braibant M, Content J, and Gilot P
- Subjects
- Amino Acid Sequence, Bacterial Proteins chemistry, Base Sequence, DNA, Bacterial genetics, Molecular Sequence Data, Sequence Alignment, Sequence Analysis, DNA, Bacterial Proteins genetics, DNA Transposable Elements, Mycobacterium bovis genetics
- Abstract
The structure and distribution of a Mycobacterium bovis BCG insertion element of the IS21 family were investigated. Several IS21-like elements found in mycobacterial genomes were separated in four types, following their nucleic acid similarities. The M. bovis BCG IS21 element is highly similar to IS1533 (class I), 70% similar to IS1534 (class II), 52% similar to IS1532 (class III) of Mycobacterium tuberculosis, and 54% similar to both an Mycobacterium avium serovar 2 and an M. avium silvaticum IS (class IV). The M. bovis BCG IS21 element of the class I appears to be present in a single copy in the genome of M. bovis BCG, M. bovis, M. tuberculosis and Mycobacterium africanum and to be absent from all other tested species of the Corynebacteria-Mycobacteria-Nocardia group.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.